Furthermore, a novel dual PI3K/mTOR inhibitor, VDC-597, showed dose-dependent inhibition of both Akt1 and 4eBP1, reduction of proliferation, migration and VEGF production, and promotion of tumor cell apoptosis in three canine HSA cell lines (Pyuen et al., 2018). Here, PIK3CA is linked to neoplasm.